 |
|
|
 | ImmunoGen Inc (NASDAQ GM:IMGN) | 9/3/2010 |  |
| THURSDAY, SEPTEMBER 02, 2010 | | 6:30 AM | ImmunoGen, Inc. Announces Webcast of Presentations at Multiple Investor Conferences in September - BusinessWire |  | | FRIDAY, AUGUST 27, 2010 | | 6:01 AM | Genentech Receives Refuse to File Letter from FDA for T-DM1 - BusinessWire |  | | THURSDAY, AUGUST 19, 2010 | | 5:33 AM | ImmunoGen Inc secures orphan drug designation for lorvotuzumab mertansine for small-cell lung cancer - M2 |  | | WEDNESDAY, AUGUST 18, 2010 | | 12:45 PM | ImmunoGen, Inc. Announces Orphan Drug Designation Granted to Lorvotuzumab Mertansine for Treatment of Small-Cell Lung Cancer - BusinessWire |  | | WEDNESDAY, AUGUST 04, 2010 | | 4:01 PM | ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results - BusinessWire |  | | THURSDAY, JULY 29, 2010 | | 6:30 AM | ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conferences - BusinessWire |  | | WEDNESDAY, JULY 28, 2010 | | 6:30 AM | ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2010 Financial Results - BusinessWire |  | | THURSDAY, JUNE 24, 2010 | | 4:03 PM | ImmunoGen, Inc. Earns Milestone with Start of SAR650984 Clinical Trial - BusinessWire |  | | TUESDAY, JUNE 22, 2010 | | 3:02 PM | ImmunoGen, Inc. Announces Vice President Promotions in Product Development - BusinessWire |  | | MONDAY, JUNE 07, 2010 | | 9:02 AM | ImmunoGen, Inc. Announces Encouraging IMGN388 Clinical Data Reported at ASCO - BusinessWire |  |
|
|
 |